EcoDrugPlus

Peptidyl-Prolyl Cis-Trans Isomerase A-Like

Ensembl ID : ENSMOCG00000006458
Gene Symbol: LOC101990675
2 Cross references
300 Possible Orthologues:

Peptidyl-Prolyl Cis-Trans Isomerase A-Like

Ensembl ID : ENSMOCG00000006904
Gene Symbol: LOC101997113
2 Cross references
299 Possible Orthologues:

Peptidyl-Prolyl Cis-Trans Isomerase A-Like

Ensembl ID : ENSMOCG00000009273
Gene Symbol: LOC101983351
2 Cross references
300 Possible Orthologues:

Peptidyl-Prolyl Cis-Trans Isomerase A-Like

Ensembl ID : ENSMOCG00000005080
Gene Symbol: LOC101992462
2 Cross references
299 Possible Orthologues:

Peptidylprolyl Isomerase A

Ensembl ID : ENSMOCG00000019036
Gene Symbol: PPIA
2 Cross references
299 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSMOCG00000014657
Gene Symbol: PPARA
3 Cross references
453 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSMOCG00000021292
Gene Symbol: PPARD
3 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSMOCG00000017202
Gene Symbol: PPARG
3 Cross references
405 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSMOCG00000013980
Gene Symbol: PIK3CA
3 Cross references
275 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSMOCG00000020793
Gene Symbol: PIK3CB
3 Cross references
215 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSMOCG00000009122
Gene Symbol: PIK3CD
1 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSMOCG00000007687
Gene Symbol: PIK3CG
3 Cross references
213 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).